Myriad Genetics, Inc. (MYGN): Price and Financial Metrics
Myriad Genetics, Inc. (MYGN)
Today's Latest Price: $11.47 USD
Updated Jul 10 4:00pm
Add MYGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
MYGN Stock Summary
- MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.85 -- higher than merely 19.55% of US-listed equities with positive expected earnings growth.
- In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -680.94%; that's higher than merely 2.89% of US stocks.
- The volatility of Myriad Genetics Inc's share price is greater than that of 80.85% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be HBIO, KVHI, DSS, CCUR, and DHX.
- MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to myriad.com.
MYGN Stock Price Chart Technical Analysis Charts
MYGN Price/Volume Stats
| Current price | $11.47 | 52-week high | $48.40 |
| Prev. close | $11.44 | 52-week low | $9.24 |
| Day low | $11.05 | Volume | 785,602 |
| Day high | $11.73 | Avg. volume | 1,172,057 |
| 50-day MA | $13.68 | Dividend yield | N/A |
| 200-day MA | $20.81 | Market Cap | 855.15M |
Myriad Genetics, Inc. (MYGN) Company Bio
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
MYGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $11.47 | $2.45 | -79% |
We started the process of determining a valid price forecast for Myriad Genetics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Myriad Genetics Inc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for MYGN, they are:
- The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.08%; that's greater than merely 18.67% of US stocks we're applying DCF forecasting to.
- Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -14.82. This coverage rate is greater than that of just 6.49% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 11. This value is greater than 87.45% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -79% |
| 1% | -79% |
| 2% | -79% |
| 3% | -79% |
| 4% | -78% |
| 5% | -78% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MYGN, try ARA, EW, PRGO, VAR, and VIVO.
Loading social stream, please wait...